These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 27676085

  • 1. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
    Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, Lee S, Petkovich PM, Bishop CW.
    Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
    [Abstract] [Full Text] [Related]

  • 2. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
    Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW.
    Am J Nephrol; 2014; 40(6):535-45. PubMed ID: 25572630
    [Abstract] [Full Text] [Related]

  • 3. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW.
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [Abstract] [Full Text] [Related]

  • 4. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.
    Petkovich M, Melnick J, White J, Tabash S, Strugnell S, Bishop CW.
    J Steroid Biochem Mol Biol; 2015 Apr; 148():283-9. PubMed ID: 25446887
    [Abstract] [Full Text] [Related]

  • 5. Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.
    Merante D, Schou H, Morin I, Manu M, Ashfaq A, Bishop C, Strugnell S.
    Nephron; 2024 Apr; 148(10):657-666. PubMed ID: 38657576
    [Abstract] [Full Text] [Related]

  • 6. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
    Galassi A, Bellasi A, Ciceri P, Pivari F, Conte F, Cozzolino M.
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
    Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B.
    J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
    [Abstract] [Full Text] [Related]

  • 8. Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.
    Bishop CW, Strugnell SA, Csomor P, Kaiser E, Ashfaq A.
    Am J Nephrol; 2022 Jul; 53(6):446-454. PubMed ID: 35551374
    [Abstract] [Full Text] [Related]

  • 9. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
    Germain MJ, Paul SK, Fadda G, Broumand V, Nguyen A, McGarvey NH, Gitlin MD, Bishop CW, Csomor P, Strugnell S, Ashfaq A.
    BMC Nephrol; 2022 Nov 11; 23(1):362. PubMed ID: 36368937
    [Abstract] [Full Text] [Related]

  • 10. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.
    Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K, Wasse H, Gutiérrez OM, Ziegler TR, Tangpricha V.
    Am J Clin Nutr; 2012 Sep 11; 96(3):672-9. PubMed ID: 22854402
    [Abstract] [Full Text] [Related]

  • 11. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
    Ennis JL, Worcester EM, Coe FL, Sprague SM.
    J Nephrol; 2016 Feb 11; 29(1):63-70. PubMed ID: 25736620
    [Abstract] [Full Text] [Related]

  • 12. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Cozzolino M, Ketteler M.
    Expert Opin Pharmacother; 2019 Dec 11; 20(17):2081-2093. PubMed ID: 31675257
    [Abstract] [Full Text] [Related]

  • 13. Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D.
    Cozzolino M, Minghetti P, Navarra P.
    J Nephrol; 2022 Apr 11; 35(3):863-873. PubMed ID: 34626363
    [Abstract] [Full Text] [Related]

  • 14. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol.
    Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, Bishop CW, Ashfaq A.
    Am J Nephrol; 2021 Apr 11; 52(10-11):798-807. PubMed ID: 34818216
    [Abstract] [Full Text] [Related]

  • 15. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C, Cheng C, Wang J, Zhang L, Purrunsing Y, Yang G, Zeng M, Huang H, Ren W, Ye Y, Ma H, Xing C, Wang N.
    Clin Nephrol; 2020 Feb 11; 93(2):65-76. PubMed ID: 31793871
    [Abstract] [Full Text] [Related]

  • 16. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
    Sprague SM, Strugnell SA, Bishop CW.
    Expert Rev Endocrinol Metab; 2017 Sep 11; 12(5):289-301. PubMed ID: 30058895
    [Abstract] [Full Text] [Related]

  • 17. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.
    Clin J Am Soc Nephrol; 2014 Feb 11; 9(2):344-53. PubMed ID: 24311704
    [Abstract] [Full Text] [Related]

  • 18. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ, Harjes LM, Dembek K, Young GS, Chew DJ, Toribio RE.
    J Vet Intern Med; 2017 May 11; 31(3):791-798. PubMed ID: 28186657
    [Abstract] [Full Text] [Related]

  • 19. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.
    Isidro ML, Ruano B.
    Endocrine; 2009 Oct 11; 36(2):305-10. PubMed ID: 19598008
    [Abstract] [Full Text] [Related]

  • 20. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.
    Kidney Int; 2014 Aug 11; 86(2):407-13. PubMed ID: 24429404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.